1. Breadth of humoral response and antigenic targets of sporozoite-inhibitory antibodies associated with sterile protection induced by controlled human malaria infection
- Author
-
John H. Adams, Ying Ying Wu, Yun Shan Goh, Robert W. Sauerwein, Alice Soh Meoy Ong, Jean-François Franetich, Peter R. Preiser, Wan Ni Chia, Cornelus C. Hermsen, Anne-Charlotte Grüner, Benoit Malleret, Anthony Siau, Georges Snounou, Laurent Rénia, Dominique Mazier, and Kaitian Peng
- Subjects
0301 basic medicine ,biology ,Malaria vaccine ,030106 microbiology ,Immunology ,Plasmodium falciparum ,biology.organism_classification ,medicine.disease ,Microbiology ,Virology ,Vaccination ,03 medical and health sciences ,030104 developmental biology ,Antigen ,Immunization ,Immunity ,parasitic diseases ,biology.protein ,medicine ,Antibody ,Malaria - Abstract
The development of an effective malaria vaccine has remained elusive even until today. This is because of our incomplete understanding of the immune mechanisms that confer and/or correlate with protection. Human volunteers have been protected experimentally from a subsequent challenge by immunization with Plasmodium falciparum sporozoites under drug cover. Here, we demonstrate that sera from the protected individuals contain neutralizing antibodies against the pre-erythrocytic stage. To identify the antigen(s) recognized by these antibodies, a newly developed library of P. falciparum antigens was screened with the neutralizing sera. Antibodies from protected individuals recognized a broad antigenic repertoire of which three antigens, PfMAEBL, PfTRAP and PfSEA1 were recognized by most protected individuals. As a proof of principle, we demonstrated that anti-PfMAEBL antibodies block liver stage development in human hepatocytes. Thus, these antigens identified are promising targets for vaccine development against malaria.
- Published
- 2016
- Full Text
- View/download PDF